Abstract
The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (BRAF V600E, RET/PTC) or signaling kinases [vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR)] involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies (sorafenib, sunitinib, axitinib, imanitib, vandetanib, pazopanib, gefitinib) in stabilizing the course of the disease. Until now, however, no consensus guidelines have been established for patient selection and more data on toxicities and side effects are needed to be collected.
Keywords: Anaplastic thyroid cancer, targeted molecular therapies, tyrosine kinase inhibitors, aurora kinase inhibitors, RET, BRAF, VEGFR, V600E, TKIs, peroxisome proliferator-activated receptor-, &, γ
Current Genomics
Title: New Targeted Therapies for Thyroid Cancer
Volume: 12 Issue: 8
Author(s): Alessandro Antonelli, Poupak Fallahi, Silvia M. Ferrari, Ilaria Ruffilli, Francesca Santini, Michele Minuto, David Galleri and Paolo Miccoli
Affiliation:
Keywords: Anaplastic thyroid cancer, targeted molecular therapies, tyrosine kinase inhibitors, aurora kinase inhibitors, RET, BRAF, VEGFR, V600E, TKIs, peroxisome proliferator-activated receptor-, &, γ
Abstract: The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (BRAF V600E, RET/PTC) or signaling kinases [vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR)] involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies (sorafenib, sunitinib, axitinib, imanitib, vandetanib, pazopanib, gefitinib) in stabilizing the course of the disease. Until now, however, no consensus guidelines have been established for patient selection and more data on toxicities and side effects are needed to be collected.
Export Options
About this article
Cite this article as:
Antonelli Alessandro, Fallahi Poupak, M. Ferrari Silvia, Ruffilli Ilaria, Santini Francesca, Minuto Michele, Galleri David and Miccoli Paolo, New Targeted Therapies for Thyroid Cancer, Current Genomics 2011; 12 (8) . https://dx.doi.org/10.2174/138920211798120808
DOI https://dx.doi.org/10.2174/138920211798120808 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immune Responses to Therapeutic Proteins in Humans - Clinical Significance, Assessment and Prediction
Current Pharmaceutical Biotechnology Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer
Current Topics in Medicinal Chemistry Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future Directions
Current Medicinal Chemistry Overview of Mechanisms of Cancer Stem Cell Drug Resistance
Current Signal Transduction Therapy Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Current Drug Targets Evolving Role of Radiopharmaceuticals in Hepatocellular Carcinoma Treatment
Anti-Cancer Agents in Medicinal Chemistry Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
Current Neuropharmacology Canonical Matches of Human MicroRNAs with mRNAs: A Broad Matrix of Position and Size
MicroRNA Chronobiology of the Neuroimmunoendocrine System and Aging
Current Pharmaceutical Design Mindfulness Practice for Glycemic Control: Could it be a New Strategy for an Old Problem? A Systematic Review and Meta-Analysis
Current Diabetes Reviews Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents
Current Medicinal Chemistry Receptor Selective Synthetic Retinoids as Potential Cancer Chemotherapy Agents
Current Cancer Drug Targets Natural Products as a Promising Therapeutic Strategy to Target Cancer Stem Cells
Current Medicinal Chemistry Overview on Anticancer Drug Design and Development
Current Medicinal Chemistry Serous BMP8A has Clinical Significance in the Ultrasonic Diagnosis of Thyroid Cancer and Promotes Thyroid Cancer Cell Progression
Endocrine, Metabolic & Immune Disorders - Drug Targets Berberine Interfered with Breast Cancer Cells Metabolism, Balancing Energy Homeostasis
Anti-Cancer Agents in Medicinal Chemistry Targeting NO Signaling for the Treatment of Osteoporosis
Current Medicinal Chemistry Biotransformation of Silybin and its Congeners
Current Drug Metabolism